STAND Clinical Trial Results Published
March 25, 2021 – Results of TB Alliance’s Phase 3 clinical trial, known as STAND, have been published in the International Journal […]
Uncategorized
TB Alliance Welcomes Drug-Resistant TB Survivors to Access Advisory Committee
NEW YORK (March 24, 2021)—TB Alliance is excited to announce the expansion of its Access Advisory Committee (AAC) to include
Amid Global Pandemic, TB Treatment Innovation Advances at an Unprecedented Pace
PRETORIA (24 March 2021)—On World TB Day, as society reflects on how COVID-19 became the world’s most lethal infection in the
TB Alliance Congratulates MSF on TB-PRACTECAL Milestone
PRETORIA (24 March 2021)—TB Alliance welcomes today’s announcement of the early closing of randomization into the TB-PRACTECAL study. TB-PRACTECAL is a
Marking the Path: Biomarker Research and MARK-TB – An Interview with Riccardo Alagna
Throughout TB Alliance’s history, it has expanded its pursuit and advocacy for various types of TB research, as it identifies
TB Alliance and GSK announce partnership to develop new TB therapeutics
NEW YORK (March 18, 2021)—TB Alliance and GSK have agreed to extend their longstanding collaboration to discover new compounds that
REMox TB Trial Paves the Way for 21st Century TB Drug Trials
In 2008, TB Alliance launched the first Phase 3 clinical trial of a new TB drug in four decades. The
ZebiAI and TB Alliance Announce Collaboration to Apply ML-Driven Discovery Platform to Tuberculosis Targets
WALTHAM, Mass., February 1, 2021 – ZebiAI, Inc., a biotech company focused on improving human health by powering machine learning (ML) to
New Report Reveals that R&D Partnerships Serving Neglected Communities have Produced Dozens of Life-Saving Innovations Since 2010
NEW YORK (28 January 2021)—The public-private initiatives that contributed to COVID-19 vaccine and drug development have showcased a model for
TB Alliance Announces First Patient Dosed with TBAJ-587 in Phase 1 Study
NEW YORK (December 15, 2020)—TB Alliance announced that on December 1, 2020 the first dose was administered to a patient